{
    "clinical_study": {
        "@rank": "43516", 
        "arm_group": {
            "arm_group_label": "Diagnostic (gallium Ga 68-edotreotide PET/CT)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies gallium Ga 68-edotreotide positron emission tomography\n      (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus\n      contrast-enhanced CT (or MRI) in diagnosing patients with neuroendocrine tumors and other\n      somatostatin receptor positive tumors. Diagnostic procedures, such as gallium Ga\n      68-edotreotide PET/CT, may help find and diagnose somatostatin receptor positive\n      neuroendocrine tumors. It is not yet known whether Ga 68-edotreotide PET/CT is as effective\n      as indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosis and staging\n      of patients with neuroendocrine tumors."
        }, 
        "brief_title": "Gallium Ga 68-Edotreotide PET/CT Compared With Indium In 111 Pentetreotide Plus Contrast-Enhanced CT (or MRI) in Diagnosing Patients With Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors", 
        "condition": [
            "Adult Medulloblastoma", 
            "Childhood Medulloblastoma", 
            "Neuroblastoma", 
            "Neuroendocrine Tumor", 
            "Somatostatinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Medulloblastoma", 
                "Neuroblastoma", 
                "Somatostatinoma", 
                "Neuroendocrine Tumors"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To compare efficacy of [68Ga]-DOTA-tyr3-Octreotide (68Ga-DOTATOC) (gallium Ga\n      68-edotreotide) PET/CT with Octreoscan (indium In 111 pentetreotide) + high-resolution,\n      contrast-enhanced CT for diagnosis and staging in patients with somatostatin receptor\n      expressing tumors.\n\n      OUTLINE:\n\n      Patients receive gallium Ga 68-edotreotide intravenously (IV) and undergo PET/CT scan.\n      Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT\n      or MRI scan. Patients may also undergo a second gallium Ga 68-edotreotide PET/CT scan within\n      3-6 months if the lesions of the first scan cannot be confirmed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent\n\n          -  Biopsy proven neuroendocrine tumor, neuroblastoma, medulloblastoma, or other\n             somatostatin receptor positive tumor\n\n          -  Off Sandostatin (octreotide acetate)-long acting release (LAR) > 4 weeks and off\n             immediate release (subcutaneous) for 12 hrs prior to 68Ga-DOTATOC PET-CT\n\n          -  Karnofsky performance status or Lansky Play Scale status of >= 50 (or Eastern\n             Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)\n\n          -  Subject is male; or is a female who is either pre-menarchal, surgically sterile (has\n             had a documented bilateral oophorectomy and/or documented hysterectomy),\n             postmenopausal (> 1 years without menses), non-lactating, or of childbearing\n             potential for whom a serum pregnancy test (with the results known prior to\n             investigational product administration) is negative; a negative serum pregnancy test\n             will be required for all female subjects with child bearing potential; if a false\n             pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be\n             consulted to determine if she is/is capable of becoming pregnant\n\n          -  No therapy other than Sandostatin since last Octreoscan + diagnostic CT\n\n          -  Fresh frozen (recommended) or paraffin fixed (required) specimen of primary or\n             metastases available for ribonucleic acid (RNA) and immunohistochemistry (IHC)\n\n        Exclusion Criteria:\n\n          -  Pregnancy or breast feeding\n\n          -  Surgical resection, chemotherapy, radiation therapy, or biologic therapy since last\n             Octreoscan + CT; continuation of the same dose of Sandostatin-LAR or subcutaneous\n             Sandostatin is allowed\n\n          -  Medical condition uncontrolled by treatment making completion of study unlikely\n\n          -  Weight more than 400 pounds (subjects who weigh more than 400 pounds will not be able\n             to fit inside the imaging machines)\n\n          -  Inability to lie still for the entire imaging time (e.g. cough, severe arthritis,\n             etc.)\n\n          -  Inability to complete the needed investigational and standard-of-care imaging\n             examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)\n\n          -  Any additional medical condition, serious intercurrent illness, or other extenuating\n             circumstance that, in the opinion of the investigator, may significantly interfere\n             with study compliance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "112", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01869725", 
            "org_study_id": "201212736", 
            "secondary_id": [
                "NCI-2013-00936", 
                "P30CA086862", 
                "R01CA167632"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnostic (gallium Ga 68-edotreotide PET/CT)", 
                "description": "Given IV", 
                "intervention_name": "gallium Ga 68-edotreotide", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "Ga-68 DOTA0-Tyr3-octreotide", 
                    "Ga-68 DOTATOC"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (gallium Ga 68-edotreotide PET/CT)", 
                "description": "Undergo gallium Ga 68-edotreotide PET/CT scan", 
                "intervention_name": "positron emission tomography/computed tomography", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Diagnostic (gallium Ga 68-edotreotide PET/CT)", 
                "description": "Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan", 
                "intervention_name": "indium In 111 pentetreotide", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "Indium-111 Octreotide DTPA", 
                    "Indium-111-DTPA-D-Phe-1-octreotide", 
                    "Indium-In 111 Pentetreotide", 
                    "Indium-In-111-Pentetreotide", 
                    "Octreoscan"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (gallium Ga 68-edotreotide PET/CT)", 
                "description": "Undergo indium In 111 pentetreotide contrast-enhanced CT scan", 
                "intervention_name": "computed tomography", 
                "intervention_type": "Procedure", 
                "other_name": "tomography, computed"
            }, 
            {
                "arm_group_label": "Diagnostic (gallium Ga 68-edotreotide PET/CT)", 
                "description": "Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan", 
                "intervention_name": "contrast-enhanced magnetic resonance imaging", 
                "intervention_type": "Procedure", 
                "other_name": "Contrast-enhanced MRI"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Octreotide", 
                "Somatostatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Neuroendocrine Tumor", 
            "Ga-DOTATOC PET", 
            "Imaging"
        ], 
        "lastchanged_date": "May 31, 2013", 
        "location": {
            "contact": {
                "email": "sue-odorisio@uiowa.edu", 
                "last_name": "M. Sue S. O' Dorisio", 
                "phone": "319-356-3595"
            }, 
            "facility": {
                "address": {
                    "city": "Iowa City", 
                    "country": "United States", 
                    "state": "Iowa", 
                    "zip": "52242"
                }, 
                "name": "University of Iowa Hospitals and Clinics"
            }, 
            "investigator": {
                "last_name": "M. Sue S. O' Dorisio", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Comparator Study of 68Ga-DOTATOC PET/CT With Octreoscan + High-resolution, Contrast-enhanced CT for Diagnosis and Staging in Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors", 
        "overall_contact": {
            "email": "suzanne-kieffer@uiowa.edu", 
            "last_name": "Suzanne Kieffer", 
            "phone": "319-530-8051"
        }, 
        "overall_official": {
            "affiliation": "University of Iowa", 
            "last_name": "M. Sue O' Dorisio", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Binomial exact tests will be used.", 
                "measure": "Equivalence of conventional imaging and gallium Ga 68-edotreotide PET using percentage of concordance in tumor detection", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "description": "Binomial exact tests will be used.", 
                "measure": "Proportion of discordance in tumor detection", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01869725"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Iowa", 
            "investigator_full_name": "O'Dorisio, M S", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Iowa", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Iowa", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}